Articles

Watchman, LAA, left atrial appendage

The long awaited U.S. Food and Drug Administration (FDA) approval of the first transcatheter left atrial appendage (LAA) occluder in March is seen by many cardiologists as a disruptive technology...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...

ACC, iPad cardiology apps

DAIC readers chose the following stories as the most popular content in 2013, based on website analytics.

Gore Helex, ASD occluder

The U.S. Food and Drug Administration (FDA) issued a warning this week about safety issues encountered with the St. Jude Amplatzer Atrial Septal Occluder (ASO), a transcatheter device used to seal...

PFM Medical

August 30, 2013 — PFM Medical received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Nit-Occlud Patent Ductus Arteriosus (PDA) device, a permanently implanted prosthesis...

Philips, TEE, mitral valve

The development of 3-D transesophageal echo (TEE) just a few years ago has enabled a new generation of interventional procedures to be performed, which otherwise would have been...

 

St. Jude Medical announced publication of results from its landmark RESPECT clinical trial in The New England Journal of Medicine.

 

Amplatzer Structural Heart Occulder Closure Device RESPECT Clinical Trial

November 8, 2012 — Results of the RESPECT clinical trial, presented at TCT 2012, indicates that using an investigational...

The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents...

Methodist DeBakey Heart and Vascular Center in Houston, Tex., has leveraged new imaging and interventional technologies to help contain and reduce costs, increase patient volume and revenues and...